Abstract 324P
Background
Poly (ADP-ribose) polymerase inhibitors (PARPi) used for maintenance therapy of patients with epithelial ovarian cancer (EOC) will eventually develop resistance. Increased expressions of ALDH1A1 and PARP1 during platinum-based chemotherapy contribute to the resistance of EOC to PARPi. All-trans retinoic acid (ATRA) has been shown to be an inhibitor of ALDH1A1 activity. We investigated whether ATRA could circumvent ALDH1A1-mediated resistance of EOC cells to Niraparib.
Methods
EOC A2780, OVCAR3 and ID8 cells were pre-treated with cisplatin for 6h, and then incubated with Niraparib or combined with ATRA for 48h. The expression of PARP1 was detected by RT-qPCR and Western Blot (WB); the inhibition of ATRA on ALDH1A1 activity was determined by ALDEFLUOR assay; the Annexin V-FITC/PI, active caspase 3 and cleaved-PARP1 for apoptosis were assayed by flow cytometry and WB, respectively; the IC50 value for Niraparib or combined with ATRA was detected by crystal violet assay; In vivo, A2780 and ID8 were implanted in female BALB/c nude and C57BL/6JGpt mice, respectively. Tumor-bearing mice were treated with four cycles of cisplatin (5mg/kg, i.p) twice a week followed by maintenance treatment with Niraparib (50 mg/kg, i.g) or combined with ATRA (0.6 mg/kg, i.p) once a day for 21 days. The volume and weight of tumor, and survival of mice were observed.
Results
All EOC cells treated with cisplatin showed higher ALDH1A1, PARP1, ALDH1A1 activity, and IC50 values for Niraparib than their parental cells, suggesting that cisplatin could lead to propagation of Niraparib resistance of EOC cells due to increased expression of ALDH1A1 and PARP1. ATRA was found to significantly (P<0.01) reduce ALDH1A1 activity and the IC50 for Niraparib, and to induce active caspase 3 and cleaved-PARP1 for apoptosis; the tumor growth was inhibited by 64.5% and 45.2%, and the median survival of tumor-bearing mice for A2780 and ID8 were extended up to 10.5 and 12.7 weeks, respectively after treatment of Niraparib combined with ATRA, compared to those of Niraparib (P< 0.01).
Conclusions
Our findings suggest that ATRA combined with Niraparib prevents increased ALDH1A1 activity-mediated resistance and improve the survival outcome for maintenance therapy of EOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
462P - Cognitive function of survivors with non-central nervous system cancer and its correlates: A community rehabilitation perspective
Presenter: Ann Kuo
Session: Poster Display
Resources:
Abstract
463P - The use of antipsychotic for managing delirium in patients with cancer
Presenter: Natasya Reina
Session: Poster Display
Resources:
Abstract
464P - The prevalence and correlates of frailty and pre-frailty in elderly patients with breast cancer: A cross-sectional study from China
Presenter: Min Xiao
Session: Poster Display
Resources:
Abstract
465P - Oncological care needs of people with mental illness: A single institution experience in Australia
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
466P - Identification of patient satisfaction predictors among women attending oncology daycare unit using validated survey questionnaire (PSS Tool): An institutional experience in central India
Presenter: Rajesh Patidar
Session: Poster Display
Resources:
Abstract
467P - Evaluation of the effectiveness of a cluster management model based on evidence-based concepts in oncology nutrition case management
Presenter: Li He
Session: Poster Display
Resources:
Abstract
468P - The patterns of use of Traditional Chinese Medicine (TCM) in cancer patients in Hong Kong
Presenter: Olivia L T Chan
Session: Poster Display
Resources:
Abstract
469P - The need of special care for adolescent and young adult (AYA) cancer survivors: Perspective from oncologists in India
Presenter: Nandini Menon
Session: Poster Display
Resources:
Abstract
470TiP - Randomised controlled trial to evaluate the efficacy and safety of moisturising creams with or without palm-oil-derived vitamin E concentrate in addition to urea-based cream or urea-based cream alone in Capecitabine-associated Palmar-Plantar Erythrodysesthesia (ECaPPE)
Presenter: Pei-Jye Voon
Session: Poster Display
Resources:
Abstract
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract